

GenCore version 4.5
Copyright (c) 1993 - 2000 compugen Ltd.

OM protein - protein search, using sw model

Run on: August 14, 2002, 09:40:13 ; Search time 30.46 Seconds

(without alignments)
466.758 Million cell updates/sec

Title: US-09-684-215A-18
perfect score: 653

Sequence: 1 TAASDNFOLSQGQGFATPI..... QTKSGGTRTGTVLAEGPPA 128

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 747574 seqs, 111073196 residues

Total number of hits satisfying chosen parameters: 747574

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_032802:*

1: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1980.DAT:*

2: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1981.DAT:*

3: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1982.DAT:*

4: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1983.DAT:*

5: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1984.DAT:*

6: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1985.DAT:*

7: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1986.DAT:*

8: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1987.DAT:*

9: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1988.DAT:*

10: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1989.DAT:*

11: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1990.DAT:*

12: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1991.DAT:*

13: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1992.DAT:*

14: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1993.DAT:*

15: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1994.DAT:*

16: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1995.DAT:*

17: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1996.DAT:*

18: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1997.DAT:*

19: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1998.DAT:*

20: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI1999.DAT:*

21: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2001.DAT:*

22: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2001.DAT:*

23: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2002.DAT:*

24: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2003.DAT:*

25: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2004.DAT:*

26: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2005.DAT:*

27: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2006.DAT:*

28: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2007.DAT:*

29: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2008.DAT:*

30: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2009.DAT:*

31: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2010.DAT:*

32: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2011.DAT:*

33: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2012.DAT:*

34: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2013.DAT:*

35: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2014.DAT:*

36: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2015.DAT:*

37: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2016.DAT:*

38: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2017.DAT:*

39: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2018.DAT:*

40: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2019.DAT:*

41: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2020.DAT:*

42: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2021.DAT:*

43: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2022.DAT:*

44: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2023.DAT:*

45: /SIDS1/gcdata/hold-geneseq/geneseq/emb1/AI2024.DAT:*

ALIGNMENTS

RESULT 1

ID AAU69899 standard; Protein; 224 AA.

AC AAU69899;

DT 30-JAN-2002 (first entry)

XX

DE Human prostate protein/M. tuberculosis Ra12 fusion protein RA12-P510S-C.

KW Human; prostate cancer; cytostatic; immunostimulant; tumour; immunogen; fusion protein.

XX

OS Chimeric - Homo sapiens.

OS Chimeric - Microbacterium tuberculosis.

OS Synthetic.

OS Chlamydia trachoma.

XX WO200173032-A2.

PN 04-OCT-2001.

PD XX

PF 27-MAR-2001; 2001WO-US09919.

XX

PR 27-MAR-2000; 2000US-0536957.

PR 09-MAY-2000; 2000US-0568100.

PR 12-MAY-2000; 2000US-0570737.

PR 13-JUN-2000; 2000US-0593793.

PR 27-JUN-2000; 2000US-0605783.

PR 10-AUG-2000; 2000US-0636215.

PR 29-AUG-2000; 2000US-0651236.

PR 06-SEP-2000; 2000US-0657279.

PR 02-OCT-2000; 2000US-0679456.

PR 10-OCT-2000; 2000US-0685166.

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

PA (CORI-) CORIXA CORP.
 XX
 PI Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Reed SG;
 PI Fanger GR, Retter MW, Stolk JA, Day CH, Kettner MW, Stolk JA, Skeiky YAW;
 PI Li SX, Wang A, Skeiky YAW, Hepler WT, Henderson RA;
 XX
 DR WPI: 2001-63932/73.
 DR N-PSDB; NAM64132.

PT New human prostate-specific polypeptides and polynucleotides useful for
 PT the diagnosis and treatment of cancer, especially prostate cancer -
 XX
 PS Example 17; Page 533-534; 57pp; English.

XX The invention relates to isolated prostate-specific
 CC polynucleotides, polypeptides, fusion proteins of the polypeptides,
 CC antibodies raised against the polypeptides (or antigenic epitopes
 CC derived from them) and antigen-presenting cells expressing the
 CC polypeptides. The antibodies are useful for detecting the presence of
 CC cancer, especially prostate cancer. The polypeptides, polynucleotides and
 CC the antigen presenting cells are useful for stimulating, polyvalent and/or expanding
 CC cells specific for a tumour protein, and for inhibiting the development
 CC of cancer especially prostate cancer. Compositions comprising the
 CC polynucleotide and/or polypeptide are useful for stimulating an immune
 CC response, and for treating cancer. The oligonucleotide is useful for
 CC detecting cancer. The present sequence is fusion protein comprising a
 CC prostate specific polypeptide of the invention.

XX Sequence 224 AA;

XX SQ

Query Match 100.0%; Score 653; DB 22; Length 224;
 Best Local Similarity 100.0%; Pred. No. 1.2e-60; Mismatches 0; Indels 0; Gaps 0;
 Matches 128; Conservative 0; MisMatches 0; Indels 0; Gaps 0;

QY 1 TRASDINFOQLSGCGFAPIQGAMAIAQOKLPRVHIGPTAFLGLGVVDNGNARVQRV 60
 Db 8 taasdnlqlsqggqfaipiqaqmaiaqkplptvhigptafqglgvvdngnqarqrq 67

QY 61 vgsAPASLGISGTDVITAVDGAPINSATAMADALNHHPGDVISVTWOTKSGGTRGNV 120
 Db 68 vgsapaaaslglistgqvitavdgapinsatamadalnhhpqdvistvwtqtksggrtgnv 127

QY 121 TLAEGPPA 128
 Db 128 tlaeqppa 135

RESULT 2

NAM01254
 ID NAM01254 standard; Protein: 224 AA.

XX AC AACM01254;

XX DT 04-OCT-2001 (first entry)

XX DE Ra12-P510S-C construct amino acid sequence.

XX KW Human; prostate cancer; prostate-specific; diagnosis; vaccine;

XX KW cytostatic; gene therapy; metastasis.

OS Homo sapiens.

XX PN WO2001151633-A2.

PD 19-JUL-2001.

XX PP 16-JAN-2001; 2001WO-US01574.

XX PR 14-JAN-2000; 2000US-0483672.

PA (CORI-) CORIXA CORP.

XX

Query Match 100.0%; Score 653; DB 22; Length 224;
 Best Local Similarity 100.0%; Pred. No. 1.2e-60; Mismatches 0; Indels 0; Gaps 0;
 Matches 128; Conservative 0; MisMatches 0; Indels 0; Gaps 0;

QY 1 TRASDINFOQLSGCGFAPIQGAMAIAQOKLPRVHIGPTAFLGLGVVDNGNARVQRV 60
 Db 8 taasdnlqlsqggqfaipiqaqmaiaqkplptvhigptafqglgvvdngnqarqrq 67

QY 61 vgsAPASLGISGTDVITAVDGAPINSATAMADALNHHPGDVISVTWOTKSGGTRGNV 120
 Db 68 vgsapaaaslglistgqvitavdgapinsatamadalnhhpqdvistvwtqtksggrtgnv 127

QY 121 TLAEGPPA 128
 Db 128 tlaeqppa 135

RESULT 3

RAU69902
 ID AAU69902 standard; Protein: 304 AA.

XX AC AAU69902;

XX DT 30-JAN-2002 (first entry)

XX DE Human /M. tuberculosis Ra12 fusion protein RA12-P775P-ORF3.

XX KW Human; prostate cancer; cytostatic; immunostimulant; tumour; immunogen;

XX KW fusion protein.

OS Chimeric - Homo sapiens.

OS Chimeric - Microbacterium tuberculosis.

OS Synthetic.

PN WO200173032-A2.

XX PD 04-OCT-2001.

XX PR 27-MAR-2001; 2001WO-US09919.

XX PR 27-MAR-2000; 2000US-0536857.

PR 09-MAY-2000; 2000US-0568100.

PR 12-MAY-2000; 2000US-0570737.

PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US09919.
 XX
 PR 27-MAR-2000; 2000US 0536857.
 PR 09-MAY-2000; 2000US 0568100.
 PR 12-MAY-2000; 2000US 0570737.
 PR 13-JUN-2000; 2000US 0593793.
 PR 27-JUN-2000; 2000US 0605783.
 PR 10-AUG-2000; 2000US 0636215.
 PR 06-SEP-2000; 2000US 0651236.
 PR 02-OCT-2000; 2000US 0679126.
 PR 10-OCT-2000; 2000US 0685166.
 XX
 PA (CORT-) CORIXA CORP.
 XX
 PI xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Kalos MD;
 PI Fanger GR, Retter MW, Stolk JA, Day CH, Vedwick TS, Carter D;
 PI Li SX, Wang A, Skeiky YAW, Hepler WT, Henderson RA;
 DR WPI; 2001-639232/73.
 XX
 PA (CORT-) CORIXA CORP.
 XX
 PI xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Reed SG;
 PI Fanger GR, Day CH, Retter MW, Stolk JA, Skeiky YAW;
 PI Wang A, Meagher MJ;
 DR WPI; 2001-425873/45.
 XX
 PT New polynucleotide encoding a prostate-specific protein, for
 PT diagnosing, monitoring and treating prostate cancer in a patient and
 PT for use in vaccines -
 XX
 PS Example 17; Page 543-544; 579pp; English.
 XX
 CC The invention relates to isolated prostate-specific
 CC polynucleotides, polypeptides, fusion proteins of the polypeptides,
 CC antibodies raised against the polypeptides (or antigenic epitopes
 CC derived from them) and antigen-presenting cells expressing the
 CC polypeptides. The antibodies are useful for detecting the presence of
 CC cancer, especially prostate cancer. The polypeptides, polynucleotides and
 CC the antigen-presenting cells are useful for stimulating and/or expanding
 CC T cells specific for a tumour protein, and for inhibiting the development
 CC of cancer, especially prostate cancer. Compositions comprising the
 CC polynucleotide and/or polypeptide are useful for stimulating an immune
 CC response, and for treating cancer. The oligonucleotide is useful for
 CC detecting cancer. The present sequence is fusion protein comprising a
 CC prostate specific polypeptide of the invention.
 XX
 Sequence 400 AA;

SQ

Query Match 100.0%; Score 653; DB 22; Length 400;
 Best Local Similarity 100.0%; Pred. No. 2.5e-60;
 Matches 128; Conservative 0; Mismatches 0; Indexes 0; Gaps 0;

Qy 1 TAASDNFOLSQGGGFAPIQGAMAIAQOKIPLPTVHIGPTAFLGLGVVDNNGARYRV 60
 Db 8 taasdnfqlsqsgggfaipiiggamaiaqkplptvhnigptaflglgvvdnngaryrv 67

Qy 61 VGSAPAAASLGLISTGDVTAVDGAAPINSATAMADALNGHHPGIVSYWTKSGTRGNV 120
 Db 68 vgsapaaaslglistgdvtavdgapinsatamadalinghpgdvisvtwqtksggrtgnv 127

Qy 121 TLAEGPPA 128
 Db 128 tlaegppa 135

RESULT 6
 AAM01262
 ID AAM01262 standard; Protein; 400 AA.
 AC AAM01262;
 XX
 DT 04-OCT-2001 (first entry)
 XX
 DE Ral2-p501S-E2 construct amino acid sequence.
 KW

Query Match 100.0%; Score 653; DB 22; Length 400;
 Best Local Similarity 100.0%; Pred. No. 2.5e-60;
 Matches 128; Conservative 0; Mismatches 0; Indexes 0; Gaps 0;

Qy 1 TAASDNFOLSQGGGFAPIQGAMAIAQOKIPLPTVHIGPTAFLGLGVVDNNGARYRV 60
 Db 8 taasdnfqlsqsgggfaipiiggamaiaqkplptvhnigptaflglgvvdnngaryrv 67

Qy 61 VGSAPAAASLGLISTGDVTAVDGAAPINSATAMADALNGHHPGIVSYWTKSGTRGNV 120
 Db 68 vgsapaaaslglistgdvtavdgapinsatamadalinghpgdvisvtwqtksggrtgnv 127

Qy 121 TLAEGPPA 128
 Db 128 tlaegppa 135

RESULT 7
 AAG83280
 ID AAG83280 standard; Protein; 487 AA.
 AC AAG83280;
 XX
 DT 05-SEP-2001 (first entry)
 XX
 DE Chlamydia trachomatis PmpC(1) fusion protein.
 XX
 KW Chlamydia; vaccine; infection; fusion protein; antigen;

KW pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;
 KW acute respiratory tract infection; CapI; CT529; OMGB;
 KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.
 XX Chlamydia trachomatis.
 OS
 XX WO200140474-A2.
 XX PD 07-JUN-2001.
 XX PR 04-DEC-2000; 2000WO-US32919.
 XX PR 03-DEC-1999; 99US-045464.
 XX PR 19-APR-2000; 2000US-055687.
 XX PR 20-JUN-2000; 2000US-0598419.
 XX PA (CORI-) CORIXA CORP.
 XX PI Probst P, Bhatia A, skeiky YAW, Fling SP, Scholler J;
 DR XX WPI; 2001-374831/39.
 XX PT Chlamydia polypeptides and fusion proteins useful for preventing pelvic
 PT inflammatory disease, trachoma, acute respiratory tract infections,
 PT atherosclerosis and heart disease -
 XX Claim 70; Page 289-290; 295PP; English.
 CC The present sequence is provided in a specification relating to
 CC compounds and methods for the treatment and diagnosis of chlamydial
 CC infection. The compounds provided include polypeptides and fusion
 CC proteins comprising immunogenic portions of Chlamydia antigens
 CC and DNA sequences encoding such polypeptides. They are useful for
 CC vaccinating against chlamydial infection, which causes pelvic
 CC inflammatory disease, trachoma, acute respiratory tract infections,
 CC atherosclerosis and heart disease.
 XX Sequence 487 AA;
 SQ
 Query Match 100.0%; Score 653; DB 22; Length 487;
 Best Local Similarity 100.0%; Pred. No. 3.2e-60; Mismatches 0; Indels 0; Gaps 0;
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TAASDNRQISQGGFAPIQGQAMAIAQOIKLPIVHGPFTAFLGLGVVDNNGARYRVY 60
 Db 8 taasdnrqisqggfaipiqa... 67
 QY 61 VGSAPASLGISTGDVITAVDGAPINSATAMADALNGHHPGDVISVTWOTKSGTRGVY 120
 Db 68 vgsapasi... 127
 QY 121 TLAEPPA 128
 Db 128 tlaeppa 135
 QY 121 TLAEPPA 128
 Db 128 tlaeppa 135
 RESULT 8
 AAGB3276 ID AAGB3276 standard; Protein; 518 AA.
 AC AAGB3276;
 XX DE 05-SEP-2001 (first entry)
 DE Chlamydia trachomatis PhoB(1) fusion protein.
 XX KW Chlamydia; vaccine; infection; fusion protein; antigen;
 KW Pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;
 KW acute respiratory tract infection; CapI; CT529; OMGB;
 KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.
 XX OS Chlamydia trachomatis.

XX PN WO200140474-A2.
 XX PD 07-JUN-2001.
 XX PR 04-DEC-2000; 2000WO-US32919.
 XX PR 03-DEC-1999; 99US-045464.
 XX PR 19-APR-2000; 2000US-055687.
 XX PR 20-JUN-2000; 2000US-0598419.
 XX PA (CORI-) CORIXA CORP.
 XX PI Probst P, Bhatia A, skeiky YAW, Fling SP, Scholler J;
 DR XX WPI; 2001-374831/39.
 XX PT Chlamydia polypeptides and fusion proteins useful for preventing pelvic
 PT inflammatory disease, trachoma, acute respiratory tract infections,
 PT atherosclerosis and heart disease -
 XX Claim 70; Page 279-280; 295PP; English.
 XX PS The present sequence is provided in a specification relating to
 CC compounds and methods for the treatment and diagnosis of chlamydial
 CC infection. The compounds provided include polypeptides and fusion
 CC proteins comprising immunogenic portions of Chlamydia antigens
 CC and DNA sequences encoding such polypeptides. They are useful for
 CC vaccinating against chlamydial infection, which causes pelvic
 CC inflammatory disease, trachoma, acute respiratory tract infections,
 CC atherosclerosis and heart disease.
 XX Sequence 518 AA;
 SQ
 Query Match 100.0%; Score 653; DB 22; Length 518;
 Best Local Similarity 100.0%; Pred. No. 3.5e-60; Mismatches 0; Indels 0; Gaps 0;
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TAASDNRQISQGGFAPIQGQAMAIAQOIKLPIVHGPFTAFLGLGVVDNNGARYRVY 60
 Db 8 taasdnrqisqggfaipiqa... 67
 QY 61 VGSAPASLGISTGDVITAVDGAPINSATAMADALNGHHPGDVISVTWOTKSGTRGVY 120
 Db 68 vgsapasi... 127
 QY 121 TLAEPPA 128
 Db 128 tlaeppa 135
 RESULT 9
 AABJ3645 ID AABJ3645 standard; Protein; 525 AA.
 AC AABJ3645;
 XX DE 02-FEB-2001 (first entry)
 DE C. pneumoniae serovar MOMP pmp gene Ra12 fusion protein.
 XX KW Chlamydial infection; sexually transmitted disease;
 KW pelvic inflammatory disease; PID; tubal obstruction; infertility;
 KW trachoma; blindness; acute respiratory tract infection;
 KW atherosclerosis; coronary heart disease; antibacterial.
 XX OS Chlamydia pneumoniae.
 XX PN WO20034483-A2.
 XX PD 15-JUN-2000.

PR	08-DEC-1999;	99WO-US29012.
PR	08-DEC-1999;	99US-0208277.
PR	08-APR-1999;	99US-0288594.
PR	01-OCT-1999;	99US-0410568.
PR	22-OCT-1999;	99US-0226571.
XX	(CORTI-) CORIXA CORP.	
PA		
PI	Probst P, Bhatia A, Skeiky Yaw, Fling SP, Jen S, Stromberg EJ;	
XX		
DR	WPI; 2000-431303/37.	
XX		
PT	Isolated polypeptide for diagnosis and treatment of Chlamydia infection	
PT	comprises immunogenic portion of Chlamydia antigen, which comprises	
PT	amino acid sequence encoded by polynucleotide sequence -	
PS	Claim 2; Pages 221-222; 256pp; English.	
XX		
CC	The present invention relates to new nucleic acid sequences and the	
CC	proteins encoded by the nucleic acid sequences. The encoded proteins	
CC	comprise an immunogenic portion of a Chlamydia antigen. The encoded	
CC	proteins are useful for the serodiagnosis and treatment of Chlamydia	
CC	infection. Chlamidiae are intracellular bacterial pathogens that are	
CC	responsible for a wide variety of human infections. C. trachomatis	
CC	infection is one of the most common sexually transmitted diseases and can	
CC	lead to pelvic inflammatory disease (PID), resulting in tubal obstruction	
CC	and infertility. Trachoma due to ocular infection with C. trachomatis is	
CC	the leading cause of preventable blindness worldwide. C. pneumonia is a	
CC	major cause of acute respiratory tract infections in humans and is also	
CC	thought to play a role in the pathogenesis of atherosclerosis and	
CC	coronary heart disease. The present sequence is a protein isolated in the	
SQ	present invention.	
Sequence	525 AA;	
XX		
Query Match	100.0%; Score 653; DB 21; Length 525;	
Best Local Similarity	100.0%; Pred. No. 3 5e-60;	
Matches	128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1 TAASDNFQLSOGQGFAPIPGQAMAIAQGKLPVHIGPTAFGLGVWDNNNGARVQRV 60	
Db	8 taasdnfqqlsqggqgfaipqgamaiaqgklpvhighptafglgvwdnnngarvqr 67	
QY	61 VGSAPAAASLGISGQDVITAVDGAPINSATAMADALNHHPGDVISVWOTKSGGTRGNV 120	
Db	68 vgsapaaaslgisgqdvitavdgapinsatamadalinghpqdivsvtwqtksggtrgnv 127	
QY	121 TLAEGPPA 128	
Db	128 tlaeqppa 135	
RESULT	10	
AAG83213	ID AAG83213 standard; Protein; 525 AA.	
XX		
AC	AAG83213;	
XX		
DT	05-SEP-2001 (first entry)	
XX		
DE	Chlamydia trachomatis PmpC(2) fusion protein.	
XX		
KW	Chlamydia; vaccine; infection; fusion protein; antigen;	
DT	pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;	
KW	acute respiratory tract infection; Cap1; CT529; OMGB; TSA.	
XX		
KW	polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.	
OS	Chlamydia trachomatis.	
XX		
PN	WO200140474-A2.	
XX		
PD	07-JUN-2001.	
XX		
PF	04-DEC-2000; 2000WO-US32919.	
XX		
PR	03-DEC-1999; 99US-0454684.	
PR	19-APR-2000; 2000US-0556877.	
PR	20-JUN-2000; 2000US-0598419.	
XX		
PA	(CORTI-) CORIXA CORP.	
XX		
PA	Probst P, Bhatia A, Skeiky Yaw, Fling SP, Scholler J;	
XX		
DR	WPI; 2001-374831/39.	
XX		
PT	Chlamydia polypeptides and fusion proteins useful for preventing pelvic	
PT	inflammatory disease; trachoma, acute respiratory tract infections,	
PT	atherosclerosis and heart disease -	
XX		
PS	Claim 2; Page 226-227; 295pp; English.	
XX		
CC	The present sequence is provided in a specification relating to	
CC	compounds and methods for the treatment and diagnosis of chlamydial	
CC	infection. The compounds provided include polypeptides and fusion	
CC	proteins comprising immunogenic portions of Chlamydia antigens	
CC	and DNA sequences encoding such polypeptides. They are useful for	
CC	vaccinating against chlamydial infection, which causes pelvic	
CC	inflammatory disease, trachoma, acute respiratory tract infections,	
CC	atherosclerosis and heart disease.	
SQ	Sequence 525 AA;	
XX		
Query Match	100.0%; Score 653; DB 22; Length 525;	
Best Local Similarity	100.0%; Pred. No. 3 5e-60;	
Matches	128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1 TAASDNFQLSOGQGFAPIPGQAMAIAQGKLPVHIGPTAFGLGVWDNNNGARVQRV 60	
Db	8 taasdnfqqlsqggqgfaipqgamaiaqgklpvhighptafglgvwdnnngarvqr 67	
QY	61 VGSAPAAASLGISGQDVITAVDGAPINSATAMADALNHHPGDVISVWOTKSGGTRGNV 120	
Db	68 vgsapaaaslgisgqdvitavdgapinsatamadalinghpqdivsvtwqtksggtrgnv 127	
QY	121 TLAEGPPA 128	
Db	128 tlaeqppa 135	
RESULT	11	
AAG83281	ID AAG83281 standard; Protein; 583 AA.	
XX		
AC	AAG83281;	
XX		
DT	05-SEP-2001 (first entry)	
XX		
DE	Chlamydia trachomatis PmpC(2) fusion protein.	
XX		
KW	Chlamydia; vaccine; infection; fusion protein; antigen;	
DT	pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;	
KW	acute respiratory tract infection; Cap1; CT529; OMGB; TSA.	
XX		
KW	polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.	
OS	Chlamydia trachomatis.	
XX		
PN	WO200140474-A2.	
XX		
PD	07-JUN-2001.	
XX		
PF	04-DEC-2000; 2000WO-US32919.	
XX		

PT inflammatory disease, trachoma, acute respiratory tract infections,
 PT atherosclerosis and heart disease
 XX
 PS Claim 70; Page 264-265; 295pp; English.
 XX
 CC The present sequence is provided in a specification relating to
 CC compounds and methods for the treatment and diagnosis of chlamydial
 CC infection. The compounds provided include polypeptides and fusion
 CC proteins comprising immunogenic portions of Chlamydia antigens
 CC and DNA sequences encoding such polypeptides. They are useful for
 CC vaccinating against chlamydial infection, which causes pelvic
 CC inflammatory disease, trachoma, acute respiratory tract infections,
 CC atherosclerosis and heart disease.
 XX
 SQ Sequence 619 AA;
 Query Match 100.0%; Score 653; DB 22; Length 619;
 Best Local Similarity 100.0%; Pred. No. 4.4e-60; Indels 0; Gaps 0;
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TAASDNFOLSGQGQFAPIQGAMAIAGQIKLPLVHIGPAPFLGLGVWDNNGNARVQRV 60
 Db 8 taesdnfqisqggqfaipqgamaiaqgkplvhigpafqglgvvdangngarvqr 67
 QY 61 VGSAPAAASIGLSTGDTIATWDGAPINSATAADALINGHHPGDVISVTWOTKSGGRTGAW 120
 Db 68 vgsapaasligstgdtiavdgapinsatamadainghpgdvisvtwqtksggrtgaw 127
 QY 121 TLAEGPPA 128
 Db 128 tlaegppa 135

RESULT 14

ID AAG83274 standard; Protein; 631 AA.
 XX
 AC AAG83274:
 XX 05-SEP-2001 (first entry)
 DE Chlamydia trachomatis Pmpf(N-term) fusion protein.
 KW Chlamydia; vaccine; infection; fusion protein; antigen;
 KW acute respiratory tract infection; Capi; Ctr29; OMCB;
 KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.
 OS Chlamydia trachomatis.
 XX
 PN WO200140474-A2.

PR 07-JUN-2001.

XX 04-DEC-2000; 2000WO-US32919.

PR 03-DEC-1999; 99US-0454684.

PR 19-APR-2000; 2000US-0556877.

PR 20-JUN-2000; 2000US-0598419.

PA (CORT-) CORIXA CORP.

XX
 PT Probst, P., Bhatia, A., Skeiky Yaw, Fling SP, Scholler J;
 DR WPI; 2001-374831/39.

PT Chlamydia polypeptides and fusion proteins useful for preventing pelvic
 PT inflammatory disease, trachoma, acute respiratory tract infections,
 PT atherosclerosis and heart disease -
 XX
 PS Claim 70; Page 274-276; 295pp; English.

CC The present sequence is provided in a specification relating to
 CC compounds and methods for the treatment and diagnosis of chlamydial
 CC infection. The compounds provided include polypeptides and fusion
 CC proteins comprising immunogenic portions of Chlamydia antigens
 CC and DNA sequences encoding such polypeptides. They are useful for
 CC vaccinating against chlamydial infection, which causes pelvic
 CC inflammatory disease, trachoma, acute respiratory tract infections,
 CC atherosclerosis and heart disease.
 XX
 SQ Sequence 631 AA;
 Query Match 100.0%; Score 653; DB 22; Length 631;
 Best Local Similarity 100.0%; Pred. No. 4.5e-60; Indels 0; Gaps 0;
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TAASDNFOLSGQGQFAPIQGAMAIAGQIKLPLVHIGPAPFLGLGVWDNNGNARVQRV 60
 Db 8 taesdnfqisqggqfaipqgamaiaqgkplvhigpafqglgvvdangngarvqr 67
 QY 61 VGSAPAAASIGLSTGDTIATWDGAPINSATAADALINGHHPGDVISVTWOTKSGGRTGAW 120
 Db 68 vgsapaasligstgdtiavdgapinsatamadainghpgdvisvtwqtksggrtgaw 127
 QY 121 TLAEGPPA 128
 Db 128 tlaegppa 135

RESULT 15

ID AAG83272 standard; Protein; 646 AA.
 XX
 AC AAG83272:
 XX 05-SEP-2001 (first entry)
 DE Chlamydia trachomatis Pmpf(N-term) fusion protein.
 KW Chlamydia; vaccine; infection; fusion protein; antigen;
 KW acute respiratory tract infection; Capi; Ctr29; OMCB;
 KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.
 OS Chlamydia trachomatis.
 XX
 PN WO200140474-A2.

PD 07-JUN-2001.

XX 04-DEC-2000; 2000WO-US32919.

XX 03-DEC-1999; 99US-0454684.

PR 19-APR-2000; 2000US-0556877.

PR 20-JUN-2000; 2000US-0598419.

PA (CORT-) CORIXA CORP.

PT Probst, P., Bhatia, A., Skeiky Yaw, Fling SP, Scholler J;

DR WPI; 2001-374831/39.

PT Chlamydia polypeptides and fusion proteins useful for preventing pelvic
 PT inflammatory disease, trachoma, acute respiratory tract infections,
 PT atherosclerosis and heart disease -
 XX
 PS Claim 70; Page 269-271; 295pp; English.

CC The present sequence is provided in a specification relating to
 CC compounds and methods for the treatment and diagnosis of chlamydial
 CC infection. The compounds provided include polypeptides and fusion
 CC proteins comprising immunogenic portions of Chlamydia antigens
 CC and DNA sequences encoding such polypeptides. They are useful for

CC vaccinating against chlamydial infection, which causes pelvic
 CC inflammatory disease, trachoma, acute respiratory tract infections,
 CC atherosclerosis and heart disease.
 XX sequence 646 AA;

Query Match 100.0%; Score 653; DB 22; Length 646;
 Best Local Similarity 100.0%; Pred. No. 4.6e-60;
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAASINFOLSOGGOFAIPQGAMATAGQIKLPTVHIGPTAFLGLGVVDNNNGARYQRY 60
 Db 8 taasdnfqlsqgggfaipqgamaaqkiklptvngptafglgvvdnnngarvqry 67

QY 61 VGSAPAASLGISTGDVITAVDGAPINSATAMADALNHHPGDVISWTQWTSGGTRGNV 120
 Db 68 vgsapaaslgistgdvitavdgapinsatamadalnghpgdviswtwqtssggrtgny 127

QY 121 TLAEGPPA 128
 Db 128 tlaeqppa 135

RESULT 16

AAGB3278 standard; Protein; 654 AA.

XX AAGB3278;
 AC AAGB3278;
 DT 05-SEP-2001 (first entry)
 DE Chlamydia trachomatis PmpB(3) fusion protein.
 KW Chlamydia; vaccine; infection; fusion protein; antigen;
 KW pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;
 KW acute respiratory tract infection; CapI; Ctr529; OMBB;
 KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.
 OS Chlamydia trachomatis.
 PN WO200140474-A2.
 XX PD 07-JUN-2001.
 XX PR 04-DEC-2000; 2000WO-US32919.
 XX PR 03-DEC-1999; 99US-0454684.
 XX PR 19-APR-2000; 2000US-0556877.
 XX PR 20-JUN-2000; 2000US-0598419.
 PA (CORT-) CORIXA CORP.
 PI Probst P, Bhatia A, Skeiky YAW, Fling SP, Scholler J;
 XX DR WPI; 2001-374831/39.
 XX PT Chlamydia polypeptides and fusion proteins useful for preventing pelvic
 PT inflammatory disease, trachoma, acute respiratory tract infections,
 PT atherosclerosis and heart disease.
 PS Claim 70; Page 284-285; 295pp; English.

The present sequence is provided in a specification relating to
 PT inflammatory disease, trachoma, acute respiratory tract infections,
 PT atherosclerosis and heart disease.

PS Claim 70; Page 293-295; 295pp; English.

The present sequence is provided in a specification relating to
 CC the treatment and diagnosis of chlamydial
 CC compounds and methods for the treatment and diagnosis of chlamydial
 CC infection. The compounds provided include polypeptides and fusion
 CC proteins comprising immunogenic portions of Chlamydia antigens
 CC and DNA sequences encoding such polypeptides. They are useful for
 CC vaccinating against chlamydial infection, which causes pelvic
 CC inflammatory disease, trachoma, acute respiratory tract infections,
 CC atherosclerosis and heart disease.

SQ Sequence 683 AA;

Query Match 100.0%; Score 653; DB 22; Length 683;
 Best Local Similarity 100.0%; Pred. No. 4.9e-60;
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1 TAASDNFOLSQGGGFAIPQGAMIAQGQKLPLTHIGPTAFLGLGVVDNNNGARVRY 60 Best Local Similarity 100.0%; Score 653; DB 22; Length 691; Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	QY	61 VGSAPAAISIGISTGDVITAVDGAPINSATAMADALNGHRRGDVISTWOTKSGGTRTGVN 120 Db 68 vgsapaaasigistgdvitavdgapinsatamadalinghrrgdvistwotksggtrtgnv 127
QY	61 VGSAPAAISIGISTGDVITAVDGAPINSATAMADALNGHRRGDVISTWOTKSGGTRTGVN 120 Db 68 vgsapaaasigistgdvitavdgapinsatamadalinghrrgdvistwotksggtrtgnv 127	QY	121 TLAEGPPA 128
QY	121 TLAEGPPA 128 	QY	121 TLAEGPPA 128
Db	128 tlaegppa 135	Db	128 tlaegppa 135
RESULT 18		RESULT 19	
AAG83271	ID AAG83271 standard; Protein; 691 AA. AC AAG83271; XX 05-SEP-2001 (first entry)	AAG83279	ID AAG83279 standard; Protein; 700 AA. AC AAG83279; XX DT 05-SEP-2001 (first entry)
XX	DE Chlamydia trachomatis Pmp(C-term) fusion protein.	XX	DE Chlamydia trachomatis PmpB(4) fusion protein.
XX	KW Chlamydia; vaccine; infection; fusion protein; antigen; pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;	XX	KW Chlamydia; vaccine; infection; fusion protein; antigen; pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;
XX	KW acute respiratory tract infection; capI; Cm529; OMGB;	XX	KW acute respiratory tract infection; capI; Cm529; OMGB;
DE	KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.	XX	KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.
XX	OS Chlamydia trachomatis.	XX	OS Chlamydia trachomatis.
XX	PN WO200140474-A2.	XX	PN WO200140474-A2.
XX	PD 07-JUN-2001.	PD 07-JUN-2001.	
XX	XX	XX	
XX	PR 03-DEC-1999; 99US-0454684.	PR 03-DEC-1999; 99US-0454684.	
XX	PR 19-APR-2000; 2000US-0556877.	PR 19-APR-2000; 2000US-0556877.	
XX	PR 20-JUN-2000; 2000US-0598419.	PR 20-JUN-2000; 2000US-0598419.	
PA	(CORI-) CORIXA CORP.	PA	(CORI-) CORIXA CORP.
XX	XX	XX	
XX	PI Probst P, Bhatia A, Skeiky YAW, Fling SP, Scholler J;	PI Probst P, Bhatia A, Skeiky YAW, Fling SP, Scholler J;	
XX	XX	XX	
XX	DR WPI; 2001-374831/39.	DR WPI; 2001-374831/39.	
XX	XX	XX	
PT Chlamydia polypeptides and fusion proteins useful for preventing pelvic	PT Chlamydia polypeptides and fusion proteins useful for preventing pelvic	PT Chlamydia polypeptides and fusion proteins useful for preventing pelvic	
PT inflammatory disease, trachoma, acute respiratory tract infections,	PT inflammatory disease, trachoma, acute respiratory tract infections,	PT inflammatory disease, trachoma, acute respiratory tract infections,	
PT atherosclerosis and heart disease -	PT atherosclerosis and heart disease -	PT atherosclerosis and heart disease -	
PS Claim 70; Page 267-268; 295pp; English.	PS Claim 70; Page 286-288; 295pp; English.	PS Claim 70; Page 286-288; 295pp; English.	
XX	XX	XX	
XX	The present sequence is provided in a specification relating to	The present sequence is provided in a specification relating to	
CC	compounds and methods for the treatment and diagnosis of chlamydial	CC	
CC	atherosclerosis and heart disease -	CC	
PS	Claim 70; Page 267-268; 295pp; English.	PS	
XX	XX	XX	
CC	The present sequence is provided in a specification relating to	CC	
CC	compounds and methods for the treatment and diagnosis of chlamydial	CC	
CC	infection. The compounds provided include polypeptides and fusion	CC	
CC	proteins comprising immunogenic portions of Chlamydia antigens	CC	
CC	and DNA sequences encoding such polypeptides. They are useful for	CC	
CC	vaccinating against chlamydial infection, which causes pelvic	CC	
CC	inflammatory disease, trachoma, acute respiratory tract infections,	CC	
CC	atherosclerosis and heart disease.	CC	
XX	Sequence 700 AA;	Sequence 700 AA;	
SQ	Query Match 100.0%; Score 653; DB 22; Length 700; Best Local Similarity 100.0%; Pred. No. 5,1e-60; Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	Query Match 100.0%; Score 653; DB 22; Length 700; Best Local Similarity 100.0%; Pred. No. 5,1e-60; Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1 TAASDNFOLSQGGGFAIPQGAMIAQGQKLPLTHIGPTAFLGLGVVDNNNGARVRY 60 1 TAASDNFOLSQGGGFAIPQGAMIAQGQKLPLTHIGPTAFLGLGVVDNNNGARVRY 60 	QY	1 TAASDNFOLSQGGGFAIPQGAMIAQGQKLPLTHIGPTAFLGLGVVDNNNGARVRY 60 Db 8 taasdnlqfqgqgfaipqgamaiaqgkplptvhigttaflglgvvdnnngarvry 67
QY	1 TAASDNFOLSQGGGFAIPQGAMIAQGQKLPLTHIGPTAFLGLGVVDNNNGARVRY 60 Db 8 taasdnlqfqgqgfaipqgamaiaqgkplptvhigttaflglgvvdnnngarvry 67	QY	61 VGSAPAAISIGISTGDVITAVDGAPINSATAMADALNGHRRGDVISTWOTKSGGTRTGVN 120 Db 68 vgsapaaasigistgdvitavdgapinsatamadalinghrrgdvistwotksggtrtgnv 127
QY	121 TLAEGPPA 128	QY	121 TLAEGPPA 128

AAG83273
ID AAG83275 standard; Protein; 715 AA.
XX
AC AAG83275;
XX
DT 05-SEP-2001 (first entry)
DE Chlamydia trachomatis PmpB(C-term) fusion protein.
KW Chlamydia; vaccine; infection; fusion protein; antigen;
KW acute respiratory tract infection; CapI; Ctr529; OMGB;
KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.
OS Chlamydia trachomatis.
XX
KW Chlamydia; vaccine; infection; fusion protein; antigen;
KW pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;
KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.
OS Chlamydia trachomatis.
XX
PN WO200140474-A2.
PD 07-JUN-2001.
PP 04-DEC-2000; 2000WO-US32919.
XX
PR 03-DEC-1999; 99US-0454684.
PR 19-APR-2000; 2000US-0556877.
PR 20-JUN-2000; 2000US-0598419.
PA (CORT-) CORIXA CORP.
XX
PT Probst P, Bhatia A, Skeiky YAW, Fling SP, Scholler J;
XX
DR WPI; 2001-374831/39.
PA (CORT-) CORIXA CORP.
XX
PT Probst P, Bhatia A, Skeiky YAW, Fling SP, Scholler J;
XX
PS WPI; 2001-374831/39.
XX
PT Chlamydia polypeptides and fusion proteins useful for preventing pelvic
PT inflammatory disease, trachoma, acute respiratory tract infections,
PT atherosclerosis and heart disease -
XX
PS Claim 70; Page 272-273; 295pp; English.
XX
PT The present sequence is provided in a specification relating to
PT compounds and methods for the treatment and diagnosis of chlamydial
PT infection. The compounds provided include polypeptides and fusion
PT proteins comprising immunogenic portions of Chlamydia antigens
PT and DNA sequences encoding such polypeptides. They are useful for
PT vaccinating against chlamydial infection, which causes pelvic
PT inflammatory disease, trachoma, acute respiratory tract infections,
PT atherosclerosis and heart disease.
XX
CC Sequence 715 AA;
CC
XX
SQ Sequence 715 AA;

Query Match 100.0%; Score 653; DB 22; Length 715;
Best Local Similarity 100.0%; Pred. No. 5.2e-60;
Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAASDNFOLSPGGPQGAIPIGOAMAYAQIKPLPTVHIGPTAFGLGQWVDNNNGARVORY 60
Db 8 taasdnlqslsqggqraipqgammalagqkplptvngtqgvwdngnqarvqry 67

QY 61 VGSAPASLIGLSTGDVTAVDGAPINSATAMADALNGHHRGADVIVSWQTKSGGTRGNV 120
Db 68 vgsapaaqlsigtgdvtavdgapinsatamadalinghpgadvivswqtksggtrgnv 127

QY 121 TLAEGPPA 128
Db 128 tlaegppa 135

Search completed: August 14, 2002, 09:40:53
Job time: 40 sec

Wed Aug 14 09:41:25 2002

us-09-684-215a-18.rag

Page 12